macular edema therapy using dexamethasone nanoparticle suspension

macular edema therapy using dexamethasone nanoparticle suspension PURPOSE To determine the effectiveness and safety of a new topical nanoparticle dexamethasone ophthalmic suspension OCS-01 (Oculis SA, Lausanne, Switzerland) in the treatment of diabetic macular edema (DME). STUDY BACKGROUND Diabetic macular edema (DME) is the main cause of visual impairment in patients with diabetic retinopathy (DR).

Meta-Analysis to Determine Optimal Therapy Strategies in Macular Degeneration

Meta-Analysis Results of Clinical Trial Aimed at Determining Optimal Therapeutic Strategies for anti-VEGF Therapy in nAMD Background of this Study Neovascular age-related macular degeneration (nAMD) affects as many as 196 million people worldwide, and is a major cause of severe vision problems including blindness. Despite its prevalence, disagreements about the treatment options

macular edema therapy using dexamethasone nanoparticle suspension